Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Brooklyn, New YorkAges 18 years+ - NCT06342284Recruiting
Collecting health data during radiation for lung cancer
This trial asks people getting radiation therapy for lung cancer to use a wearable device and smartphone app to track their activity and symptoms. The goal is to learn how this treatment affects patients day-to-day.
New York, New YorkAges 18 years+ - NCT06350500Recruiting
Patient navigation for breast cancer care barriers
This study helps women with a new breast cancer or DCIS diagnosis who face barriers to care. A patient navigator will work with you to address issues like transportation, insurance, or other needs so you can get the care you need.
Buffalo, New YorkAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
New York, New YorkAges 18 years+ - NCT05606133Recruiting
Test HPV DNA from blood to track cervical cancer risk
This study looks at a blood test that measures HPV DNA to help screen and monitor people with HPV-related cervical problems. If you have confirmed high-grade cervical changes or cervical cancer, the test may help doctors follow how your condition changes over time.
New York, New YorkAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
TUB-040 for advanced ovarian or lung cancer after standard treatments fail
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
New York, New YorkAges 18 years+ - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Ithaca, New YorkAges 18 years+ - NCT06312124Recruiting
Fallopian tube removal to prevent ovarian cancer
This study looks at removing fallopian tubes during other planned surgeries to help prevent ovarian cancer. You may be able to join if you are at least 45 years old, are female or assigned female at birth, and are having non-gynecologic surgery (like gallbladder or hernia repair).
Commack, New YorkAges 45 years+ - NCT06313853Recruiting
Communication support for older adults with dementia and cancer
This study tests a communication coaching session to help older adults with both dementia and cancer talk with their family and doctors about treatment decisions. The goal is to make sure your wishes and needs are heard.
Rochester, New YorkAges 65 years+ - NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
New York, New YorkAges 15 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
New York, New YorkAges 18 years+ - NCT06283251Recruiting
RISE support program for children with cancer
This study tests a program called RISE that helps families with low income manage the financial and emotional challenges of childhood cancer treatment. It aims to see if the program is feasible and helpful for families like yours.
New York, New YorkAges Up to 17 years - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
New York, New YorkAges 12 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
New York, New YorkAges 18–130 - NCT06235697RecruitingPhase 3
Hormone therapy with or without lymph node radiation for prostate cancer
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
New York, New YorkAges 18 years+ - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
Stony Brook, New YorkAges 18 years+ - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
New York, New YorkAges 18 years+ - NCT06206863Recruiting
Physical activity program for cancer survivors and caregivers
This trial tests a community-based physical activity program designed for people who have had cancer or care for someone who has. The goal is to see if it can help improve health and well-being for those not currently on active treatment.
Buffalo, New YorkAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
New York, New YorkAges 18 years+ - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Lake Success, New YorkAges 18 years+ - NCT06184594Enrolling by invitation
Using eNav Toolkit to boost colon cancer screening
This trial tests a computer program (eNav Toolkit) to help people decide about colon cancer screening. If you are between 45 and 75 and due for screening, this study may help you make an informed choice.
New York, New YorkAges 45–75 - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Bay Shore, New YorkAges 18 years+ - NCT06172283Recruiting
Intermittent fasting with hormone therapy for prostate cancer
This trial tests whether intermittent fasting (alternating between eating and not eating for certain periods) can help men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). It aims to see if fasting during treatment can reduce side effects or improve how well the therapy works.
Buffalo, New YorkAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Syracuse, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 4 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 3 studies
- Research Site · 3 studies
- Lenox Hill Hospital · 2 studies
- Roswell Park Comprehensive Cancer Center · 2 studies
- Associated Medical Professionals of Ny
- Associated Medical Professionals of NY
- Cayuga Medical Center
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.